PLEASE NOTE

Microsoft has ended support for its pre-IE11 browsers as of January 2016 and will be discontinuing IE11 support in August 2021.

If you are seeing this message, you are viewing the site on one of these unsupported browsers. We only support the recent versions of major browsers such as Chrome, Firefox, Safari, and Edge.

Thank you.

(click to close and continue using this browser)

 contact privacy policy profile Search log in
HomeAbout

About

Executive Summary

Created, owned and operated by its members, the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) is a clinical research investigator network of over 400 members from more than 200 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO).

SUO-CTC pursues clinical trials, in concert with sponsors, to investigate therapeutic interventions which address urological cancers including, but not restricted to:

  • Bladder Cancer
  • Prostate Cancer
  • Renal Cancer

Together with industry, the SUO-CTC offers enhanced research options for ultimately delivering better quality of life to our patients.

Many of the drugs, diagnostics, and devices used in the treatment of urologic malignancies have been developed by pharmaceutical and biotechnology companies. Consequently, communication between urologic oncologists and the private sector is essential for the transfer of technology, creating opportunities for translating these advancements towards the care of patients with genitourinary malignancies.

Identifying relevant targets and managing clinical trials is increasingly complex. In the past, medical oncologists investigated a steady stream of drugs from the NCI for the conduct of phase II trials based primarily on endpoints defined by radiographic response. Today, clinical trials usually involve a multi-disciplinary approach and partnerships with industrial sponsors. They almost always include serum banking and tissue collection for the evaluation of biologically based surrogate endpoints; patients are now treated with significantly lower disease burden which requires much longer follow-up for clinical outcome and “hard” endpoints such as survival. Modern clinical trials are logistically complex, data rich, and exist in an increasingly difficult regulatory milieu.

The SUO Clinical Trials Consortium (SUO-CTC) will fill the need for dedicated expertise and clinical input into the design of urology focused clinical trials and patient recruitment. Additionally, the SUO-CTC will take primary responsibility for delivery (i.e., reporting from supporting information systems) of clinical and translational research data to the Society of Urologic Oncology and the academic community at large.

Goals and Objectives

  1. To encourage and coordinate clinical research in urologic oncology by formulating and performing network clinical trials involving therapeutic, diagnostic or prognostic procedures.
  2. To cooperate and liaise with other organizations interested in urologic oncology.
  3. To support studies of tumor biology in urologic oncology.
  4. To improve the care of patients with urologic health concerns.
  5. To advance knowledge and improve the standards of education and practice of urologic oncology.